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Abstract
Vascular endothelial growth factor (VEGF) is a potent cytokine that binds to specific receptors on the endothelial cells
lining blood vessels. The signaling cascade triggered eventually leads to the formation of new capillaries, a process
called angiogenesis. Distributions of VEGF receptors and VEGF ligands are therefore crucial determinants of angiogenic
eventsand,to ourknowledge,no quantification ofabluminal vs. luminal receptors hasbeen performed. We formulatea
molecular-based compartment model to investigate the VEGF distribution in blood and tissue in humans and show
that such quantification would lead to new insights on angiogenesis and VEGF-dependent diseases. Our multiscale
model includes two major isoforms of VEGF (VEGF121 and VEGF165), as well as their receptors (VEGFR1 and VEGFR2) and
the non-signaling co-receptor neuropilin-1 (NRP1). VEGF can be transported between tissue and blood via
transendothelial permeability and the lymphatics. VEGF receptors are located on both the luminal and abluminal
sides of the endothelial cells. In this study, we analyze the effects of the VEGF receptor localization on the endothelial
cells as well as of the lymphatic transport. We show that the VEGF distribution is affected by the luminal receptor
density. We predict that the receptor signaling occurs mostly on the abluminal endothelial surface, assuming that VEGF
is secreted by parenchymal cells. However, for a low abluminal but high luminal receptor density, VEGF binds
predominantly to VEGFR1 on the abluminal surface and VEGFR2 on the luminal surface. Such findings would be
pertinent to pathological conditions and therapies related to VEGF receptor imbalance and overexpression on the
endothelial cells and will hopefully encourage experimental receptor quantification for both luminal and abluminal
surfaces on endothelial cells.
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Introduction
Physiologic angiogenesis, the growth of new capillaries from
pre-existing blood vessels, occurs in wound healing, pregnancy,
exercise, and embryonic development. Diseases such as cancer and
age-related macular degeneration are angiogenesis-dependent [1].
The growth of new capillaries from pre-existing blood vessels is
mediated by several growth factors, one of which is a potent family
of cytokines called vascular endothelial growth factor (VEGF). The
VEGF familyis composed offive members:VEGF-A(often referred
to as VEGF), VEGF-B, VEGF-C, VEGF-D and placental growth
factor (PlGF). Alternative splicing of VEGF-A provides about 13
different VEGF isoforms [2,3]. Human VEGF consists of at
least seven isoforms: VEGF121,V E G F 145, VEGF148, VEGF165,
VEGF183,V E G F 189, and VEGF206 [4,5]. Although VEGF121,
VEGF165,V E G F 183 are diffusible, VEGF189 and VEGF206 are
mainly sequestered in the extracellular matrix [4]. Amongst the
major isoforms (with length 121, 165, 189 and 206 amino acids),
VEGF121 and VEGF165 are more highly expressed than VEGF189
and VEGF206. Furthermore, the roles of VEGF189 and VEGF206 in
vivo remain to be clearly identified [3]. For these reasons, we only
consider VEGF121 and VEGF165 isoforms in the present model.
These two isoforms bind VEGF receptors, VEGFR1 (fms-related
tyrosine kinase 1 or Flt-1 in humans) and VEGFR2 (kinase insert
domain receptor also designated as Flk-1, or KDR in humans).
VEGF165 binds to the non-signaling co-receptor neuropilin-1
(NRP1) as well and serves as a bridge for the VEGFR2-NRP1
complex. It has been shown recently that VEGF121 mayalsobind to
NRP1; however, this binding is not sufficient to bridge the
VEGFR2-NRP1 complex [6]. Preliminary sensitivity analyses from
our group suggest that incorporation of the binding between
VEGF121 and NRP1 does not drastically change the predictions
regarding the VEGF distribution [7]. Therefore, this binding is not
included in the model at the moment; this can be modified when
more information becomes available. Finally, VEGF165 contains a
heparin binding domain, which allows it to bind to the heparan
sulfate glycosaminoglycan (GAG) chains of the extracellular matrix
and the cellular basement membranes [8].
We have introduced a compartment model of VEGF distribu-
tion in the human body [9]. In the ‘‘healthy’’ set-up, the system
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system) and the rest of the body. A third compartment was added
for pathological cases to distinguish the diseased from the healthy
tissue. VEGF121, VEGF165, and their respective interactions with
VEGFR1, VEGFR2 and NRP1 were considered. VEGF was
secreted by the parenchymal cells (in the healthy tissue) and the
tumor cells (when the diseased tissue was assumed to be a breast
cancer tumor). Other elements in the blood, such as platelets and
granulocytes, sequester large amounts of VEGF and could
potentially release significant amounts of VEGF as well [10]; the
role of these processes in VEGF balance in the body is not known.
However, since the rates of VEGF release from these blood
elements have not been quantified, we have decided, as a first
approximation, to neglect explicit representation of these sources;
a distinct mathematical term can be added to the equations to
model VEGF release from these elements in the future. We
assume that the compartments are well-mixed and that freely
diffusible (unbound) VEGF is transported by vascular permeability
between the tissues and the blood.
The model presented here is an extension of our previously
published model [9], as was a recent study that analyzed the
effects of soluble VEGFR1 [7,11]. Two major additions were
made. First, lymphatic drainage of VEGF was added, serving
as a second route for VEGF to be transported from the tissue
to the blood compartment. Secondly, our previous model
considered VEGF receptors to be solely expressed on the
abluminal endothelial surface. Here, we included the presence
of VEGF receptors and co-receptor NRP1 on the luminal
endothelial surface based on the evidence that VEGFR2
(Flk-1, KDR) is also present on the luminal endothelial surface
[12].
We hypothesize that the distribution of VEGF receptors
between the abluminal and luminal surfaces of the endothelial
cells (i.e., present solely on the abluminal endothelial surface;
present solely on the luminal endothelial surface; or present on
both surfaces of the endothelial cells) can impact the VEGF
ligand distribution in the tissue and in the blood, as well as the
VEGF signaling efficiency. The focus of this paper is to
investigate the effects of receptor repartition on endothelial
cellular surfaces and emphasize the importance of receptor
quantification.
Materials and Methods
Geometry. The model has been fully described in our
previous paper [9]. To summarize, we distinguish between the
vascular system (blood) and the rest of the body (represented by
skeletal muscle). The tissue is divided into parenchymal cells and
capillaries, separated by the interstitial space. This space is further
subdivided into the extracellular matrix (ECM) and the basement
membranes of the parenchymal cells and of the endothelial cells
(PBM and EBM respectively). Secreted by parenchymal cells in
the tissue, VEGF isoforms VEGF121 and VEGF165 diffuse freely
and bind to VEGF receptors and neuropilin-1 that are expressed
on the endothelial surfaces, as shown in Figure 1A.
Computational model. A schematic of the computational
design is illustrated in Figure 1B. We distinguish between the
vascular system (‘‘blood compartment’’) and the tissue (‘‘tissue
compartment’’). The tissue compartment is divided into two parts:
the parenchymal cells where VEGF is secreted, and the
interstitium. However, because the extracellular matrix is a
porous medium, and because some pores are not accessible to
freely diffusible molecules, only a fraction of the interstitial space is
accessible to VEGF. This accessible region, called available fluid
volume UAV, is to be distinguished from the rest of the interstitial
space. It is possible to link the available fluid volume to the total
volume of the tissue U by the relation UAV=K AV.U , where KAV
represents the ratio between the available fluid interstitial space to
the total volume, and can be expressed as the product of the
partition coefficient and the porosity of the medium. Similarly, we
partition the blood into plasma and the rest of the blood. Further
details about the available fluid volumes for VEGF can be found in
our previous study [9].
The model includes the expression of receptors on the luminal
and abluminal endothelial surfaces as well as their internalization.
In the mathematical setup, the receptors expressed on the
abluminal endothelial surface are considered to be part of the
‘‘tissue compartment’’ while the receptors expressed on the
luminal endothelial surface are part of the ‘‘blood compartment.’’
This permits a clear distinction between the two surfaces of the
endothelial cells and their receptor expressions as illustrated in
Figure 1B.
Inter-compartment transport modes include vascular perme-
ability and lymphatic removal. VEGF can extravasate and
intravasate (bi-directional microvascular permeability). Note that
hemodynamics is not considered in this compartment model
because there is no evidence that the transport of VEGF is blood
flow limited. The cytokine can also be drained from the tissue into
the blood (unidirectional lymphatic drainage) or cleared from the
plasma (e.g., by the kidneys or the liver, organs that are not
explicitly represented in the model).
Figure 1C summarizes the biochemical reactions that are
included in our model. We consider two VEGF isoforms:
VEGF121 and VEGF165. Both isoforms bind to two receptor
tyrosine kinases: VEGFR1 and VEGFR2. VEGF-VEGFR
complex formation induces signal transduction in vivo. The model
also includes the binding of VEGF165 to neuropilin-1 (NRP1).
Although VEGF121 has been shown to bind to NRP1 as well, this
binding does not bridge VEGFR2-NRP1 complex as VEGF165
does [6]. The inclusion of such binding to our model does not
significantly affect the VEGFR2 signaling pathway, nor does it
significantly change the VEGF distribution profile [7]. Therefore,
our present model does not include the possibility of VEGF121-
NRP1 complex formation, but this could be readily added when
kinetic information and quantitative data become available.
Ternary groups can be formed either by the coupling of NRP1
Author Summary
Angiogenesis is the growth of new blood vessels from pre-
existing vasculature that occurs in physiological (e.g.,
exercise) and pathological contexts (e.g., cancer). This
process is often triggered by a signaling cascade that
occurs upon ligand-receptor binding between vascular
endothelial growth factor (VEGF) and its receptors
(VEGFR1/Flt-1, VEGFR2/KDR). These receptors are ex-
pressed by endothelial cells that line the blood vessels.
Little is known about the quantitative proportion of
abluminal receptors (facing the tissue) as compared to
those on the luminal surface (facing the blood). We have
built a compartment model with molecular details from
human tissues to investigate why such experimental data
would be of importance. We conclude that the receptor
distribution on the endothelial cells can significantly alter
the VEGF distribution and the VEGF signaling (through its
binding to the receptors) and that quantification of
luminal vs. abluminal VEGF receptors would shed light
on VEGF signaling and VEGF-dependent mechanisms of
angiogenesis.
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VEGFR2 and NRP1 to form a VEGFR2-VEGF165-NRP1 triplet.
Besides binding to VEGFR1, VEGFR2 and NRP1, VEGF165
contains a heparin-binding domain that permits the isoform to be
sequestered by the extracellular matrix or the cellular basement
membranes.
Biochemical kinetic equations. The equations as well as a
glossary of each term are summarized in Text S1. The
concentrations are all expressed in moles/cm
3 tissue. The
equations (S.18) and (S.20) describing the temporal dependence
of the free ligand concentrations in the available fluid interstitial
space need to be modified to take into account the introduction of
lymphatic drainage of VEGF from the tissue to the blood.
dV 121 ½  N
dt
~qN
V121{kN
on,V121,R1 V121 ½  N R1 ½  NzkN
off,V121R1 V121R1 ½  N
{kN
on,V121,R1N1 V121 ½  N R1N1 ½  NzkN
off,V121R1N1 V121R1N1 ½  N
{kN
on,V121,R2 V121 ½  N R2 ½  NzkN
off,V121R2 V121R2 ½  N
{
kLzkNB
pV SNB
UN
 !
V121 ½  N
KAV,N
zkBN
pV
SNB
UN
UB
Up
V121 ½  B
ð1Þ
dV 165 ½  N
dt
~qN
V165{kN
on,V165,MEBM V165 ½  N MEBM ½  N
zkN
off,V165,MEBM V165MEBM ½  N{kN
on,V165,MECM V165 ½  N MECM ½  N
zkN
off,V165MECM V165MECM ½  N{kN
on,V165,MPBM V165 ½  N MPBM ½  N
zkN
off,V165MPBM V165MPBM ½  N{kN
on,V165,R1 V165 ½  N R1 ½  N
zkN
off,V165R1 V165R1 ½  N{kN
on,V165,R2 V165 ½  N R2 ½  N
zkN
off,V165R2 V165R2 ½  N{kN
on,V165,N1 V165 ½  N N1 ½  N
zkN
off,V165N1 V165N1 ½  N{
kLzkNB
pV SNB
UN
 !
V165 ½  N
KAV,N
zkBN
pV
SNB
UN
UB
Up
V165 ½  B
ð2Þ
where kL is the lymph flow rate (in cm
3/s). The physical meaning
of each term is described in Text S1.
In the blood compartment, the introduction of luminal
receptors leads to new equations: the equations (S.7) to (S.17)
governing the unligated and ligated receptor concentrations in the
tissue compartment are now applicable to the blood compartment
as well. The introduction of the VEGF lymphatic drainage also
changes equations (S.21) and (S.22) describing the temporal
dependence of the free ligand concentrations in the plasma. We
use kL to denote the rate of lymphatic flow rate from the tissue to
the blood. Equations (S.21) and (S.22) become
dV 121 ½  B
dt
~{cV121 V121 ½  B{kB
on,V121,R1 V121 ½  B R1 ½  BzkB
off,V121R1 V121R1 ½  B
{kB
on,V121,R1N1 V121 ½  B R1N1 ½  BzkB
off,V121R1N1 V121R1N1 ½  B
{kB
on,V121,R2 V121 ½  B R2 ½  BzkB
off,V121R2 V121R2 ½  B
{
kBN
pV SNB
Up
V121 ½  Bz
kLzkNB
pV SNB
UB
 !
V121 ½  N
KAV,N
ð3Þ
Figure 1. Compartment model. A. Schematic of a tissue cross
section. B. Compartment model. The vascular system is separated from
the rest of the body. The blood compartment comprises the plasma
(available to VEGF), the blood elements (blood cells, fibrin, clotting
elements, etc.), as well as the luminal side of the basement membranes
of the endothelial cells. The tissue compartment is composed of the
parenchymal cells that secrete VEGF, the interstitium as well as the
abluminal surface of the endothelial cells lining the capillaries. The
fraction that is not accessible to VEGF is represented as a hatched area.
The arrows illustrate inter-compartment and intra-compartment ex-
changes: secretion, vascular permeability, internalization of the
receptors, lymphatic drainage, and clearance from the plasma. C.
Schematic of the chemical interactions. Two isoforms of VEGF are
considered: VEGF121 and VEGF165. Free receptors (VEGFR1, VEGFR2 and
NRP1) and free VEGF isoforms are located in the gray areas. VEGF121 and
VEGF165 both bind VEGFR1 and VEGFR2. VEGF165 also binds glycosami-
noglycan chains (GAG) as well as the co-receptor NRP1. VEGF165 can
serve as a bridge for the formation of VEGFR2-NRP1 complex. Finally,
VEGF121 can bind to VEGFR1-NRP1 complex.
doi:10.1371/journal.pcbi.1000622.g001
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dt
~cV165 V165 ½  B{kB
on,V165,R1 V165 ½  B R1 ½  BzkB
off,V165R1 V165R1 ½  B
{kB
on,V165,R2 V165 ½  B R2 ½  BzkB
off,V165R2 V165R2 ½  B
{kB
on,V165,N1 V165 ½  B N1 ½  BzkB
off,V165N1 V165N1 ½  B
{
kBN
pV SNB
Up
V165 ½  Bz
kLzkNB
pV SNB
UB
 !
V165 ½  N
KAV,N
ð4Þ
Numerical implementation. The system is described by 32
ordinary non-linear differential equations (19 for the tissue
compartment and 13 for the blood compartment). These
equations and the initial conditions were implemented using
Visual FORTRAN 6 software on a PC. Transient solutions were
calculated using an adaptive step-size Runge-Kutta 5
th-order
accuracy integrative scheme. A relative error tolerance of 10
25
was used. The steady state was defined when the concentrations
changed by less than 1%.
Model parameters. The parameters are summarized in
Tables 1–5. We model a 70-kg human subject. This includes 5.154
liters of total blood, of which 54.3% constitutes the blood plasma
(2.717 liters).
The volume of the normal tissue corresponds to that of a 70-kg
human subject with a skeletal muscle density of 1.06 g/cm
3 after
subtracting 5,154 cm
3 of whole blood, i.e., 61,321 cm
3. The
parameters and the properties of the skeletal muscle (tissue
compartment) are summarized in Tables 1–4. Briefly, the fluid
volume fractions available for VEGF in the extracellular matrix,
the parenchymal basement membrane and the endothelial
basement membrane are 6.1987%, 0.0307% and 0.0087% of
the total tissue respectively (Table 1). Thus, the interstitial fluid
volume accessible by VEGF is 6.2381% of the total volume
(Table 4). Total VEGF expression isoform ratio VEGF165:-
VEGF121 is taken to be 92%:8% [13].
We assume conservation of the density of receptors (ligated and
unligated). In other words, at any time step, the density of
receptors newly expressed on each membrane surface (luminal or
abluminal) of the endothelial cells equals the density of receptors
being internalized on that same surface. This assumption can be
relaxed when more information on VEGF receptor dynamics
become available.
Inter-compartment transport includes VEGF extravasation and
intravasation (bidirectional transcapillary exchange) as well as
lymphatic drainage of VEGF from the tissue to the blood. Unless
specified otherwise, the vascular permeability to VEGF molecule is
taken to be 4610
28 cm/s in accordance with our previous model
[9]. The lymphatic drainage in skeletal muscle of a healthy subject
in the asleep, supine position has been reported to be between 1.7
and 2.5 mL/h/g [7,14]. The total lymph flow rate at rest is
estimated at 120 mL/hour [15], i.e., 2 cm
3/min or 2.88 L/day
(Table 5). As a first approximation, we assume that the removal
rate of VEGF from our tissue compartment through the
lymphatics corresponds to this lymph flow rate.
Table 1. Geometric parameters for the tissue (human vastus lateralis muscle).
Skeletal muscle characteristic Parameter Value Unit Ref
Muscle fibers Cross-sectional area of one fiber 3000 mm
2 [18]
Perimeter of one fiber 222 mm [18]
Capillary-fiber ratio 1.38 [23]
Capillary density 420 capillaries/mm
2 tissue [18]
Muscle fiber density 304 fibers/mm
2 tissue [18]
Volume fractions Interstitial space 8.16% cm
3/cm
3 tissue [24,25]
Fibers 89.98% cm
3/cm
3 tissue [18]
Microvessels 1.86% cm
3/cm
3 tissue [18]
of which vascular space 1.4% cm
3/cm
3 tissue [26]
Microvessels Internal diameter of microvessel 6.56 mm [18]
Thickness of endothelial cell 0.5 mm [27]
External diameter of microvessel 7.56 mm [18]
Cross-sectional area of one microvessel 45 mm
2 [18]
Perimeter of one microvessel 26 mm [18]
Surface areas Muscle fibers 664 cm
2/cm
3 tissue [18]
Microvessels 108 cm
2/cm
3 tissue [18]
Basement membranes (BM) Thickness of muscle fiber BM 24 nm [28]
Basement membrane volume (muscle fiber) 0.00159 cm
3/cm
3 tissue [9]
of which available to VEGF 0.000307 cm
3/cm
3 tissue [9]
Thickness of microvessel BM 43 nm [28]
Basement membrane volume (microvessel) 0.00045 cm
3/cm
3 tissue [9]
of which available to VEGF 0.000087 cm
3/cm
3 tissue [9]
Extracellular matrix volume 0.07951 cm
3/cm
3 tissue [9]
of which available to VEGF 0.061987 cm
3/cm
3 tissue [9]
Skeletal muscle nuclear
domain (SMND) surface area
1850 mm
2 [18]
doi:10.1371/journal.pcbi.1000622.t001
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from plasma of 0.0206 min
21, corresponding to a VEGF half-life
of approximately 34 min [9]. This was based on simple non-
compartmental pharmacokinetic analysis of raw experimental data
by Eppler et al. [16], which lumps together all routes of VEGF
elimination from plasma. In order to better estimate the direct
VEGF clearance rate from plasma (through protein degradation
or kidney filtration, etc.), as distinct from alternate routes such as
receptor-mediated metabolism or disappearance of extravasated
VEGF by ligated receptors after biodistribution to muscle tissue
Table 2. Kinetic parameters of VEGF in the tissue (human vastus lateralis muscle).
Reaction Parameter Measured parameter Tissue Model
Value Unit Value Unit
VEGF binding to VEGFR1 kon 31 0
7 M
21 s
21 4.8 10
21 (pmol/cm
3 tissue)
21 s
21
koff 10
23 s
21
Kd 33 pM 2.0 10
23 pmol/cm
3 tissue
VEGF binding to VEGFR2 kon 10
7 M
21 s
21 1.6 10
21 (pmol/cm
3 tissue)
21 s
21
koff 10
23 s
21
Kd 100 pM 6.4 10
23 pmol/cm
3 tissue
VEGF165 binding to NRP1 kon 3.2 10
6 M
21 s
21 5.1 10
22 (pmol/cm
3 tissue)
21 s
21
koff 10
23 s
21
Kd 312 pM 2.0 10
22 pmol/cm
3 tissue
VEGF165 binding to GAGs kon 4.2 10
5 M
21 s
21 6.7 10
23 (pmol/cm
3 tissue)
21 s
21
koff 10
22 s
21
Kd 24 nM 1.5 pmol/cm
3 tissue
Coupling of NRP1 & VEGFR2 kcV165R2,N1 3.1 10
13 (mol/cm
2)
21 s
21 2.8 10
21 (pmol/cm
3 tissue)
21 s
21
koffV165R2,N1 10
23 s
21
kcV165N1,R2 10
14 (mol/cm
2)
21 s
21 9.2 10
21 (pmol/cm
3 tissue)
21 s
21
koffV165N1,R2 10
23 s
21
VEGFR1 coupling to NRP1 kcR1,N1 10
14 (mol/cm
2)
21 s
21 9.2 10
21 (pmol/cm
3 tissue)
21 s
21
kdissocR1,N 10
22 s
21
VEGFR internalization kint,R 2.8 10
24 s
21
kint,C 2.8 10
24 s
21
In this table, 6.24 10
7 (pmol/cm
3 tissue)/M and 1.09 10
14 (pmol/cm
3 tissue)/(mol/cm
2 EC). Here, M=moles/liter available interstitial fluid volume. The derivation of these
parameters is found in [18].
doi:10.1371/journal.pcbi.1000622.t002
Table 3. VEGF concentration and receptor densities for the tissue (human vastus lateralis).
Category Parameter Measured parameter Tissue model
Value Unit Value Unit
Free VEGF concentration Human vastus lateralis, rest 1 pM 6.2 10
25 pmol/cm
3 tissue
Total VEGF tissue concentration Human vastus lateralis, rest 1–2 pg/mg protein 3.4–6.9 pmol/cm
3 tissue
VEGFR1 tissue concentration Human vastus lateralis, rest 1.6–1.8 pg/mg protein 1.1–1.2 pmol/cm
3 tissue
60,000–68,000 #/EC
VEGFR2 tissue concentration Human vastus lateralis, rest 0.33–0.5 pg/mg protein 0.24–0.34 pmol/cm
3 tissue
13,000–19,000 #/EC
NRP1 tissue concentration 0.018–1.8 pmol/cm
3 tissue
1,000–100,000 #/EC
ECM binding site density ECM 0.75 mM 46 pmol/cm
3 tissue
Vessel BM 13 mM 1 pmol/cm
3 tissue
Myocyte BM 13 mM 4 pmol/cm
3 tissue
The conversion of receptor densities to tissue: see table 2. Endothelial cell surface area=1000 mm
2. Conversions are as follow: VEGF concentration: 6.2 10
7 (pmol/cm
3
tissue)/M (here, M=moles/liter interstitial fluid available to VEGF); VEGF binding sites in the ECM and BMs: 6.2 10
7 (pmol/cm
3 tissue)/M (ECM fluid accessible to VEGF),
5.7 10
4 (pmol/cm
3 tissue)/M (EBM fluid accessible to VEGF), 3.1 10
5 (pmol/cm
3 tissue)/M (MBM fluid accessible to VEGF). For example, M(EBM)=moles/liter endothelial
basement membrane. Conversions from pg/mg protein are based on 155 mg protein/g of tissue and 45 kDa VEGF, 210 kDa VEGFR1, 240 kDa VEGFR2 [18].
doi:10.1371/journal.pcbi.1000622.t003
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representation in our model), we have adopted a theoretical
clearance rate derived by Eppler et al. [16] through physiological
mechanism-based compartmental biodistribution modeling, which
predicts an elimination rate of 3.89 hr
21, corresponding to a
clearance rate of VEGF from the plasma of 0.0648 min
21
(Table 5).
The VEGF plasma concentration in healthy subjects has been
typically measured between 0.5–1.5 pM [17]. Unless specified
otherwise, we maintain the average VEGF plasma concentration
,1 pM in this model as a baseline. Note that the results are
dependent on the expression of the receptors the quantitative
knowledge of which in vivo is very limited.
Results
Free VEGF concentration in plasma is significantly
altered by the change of VEGF clearance rate from
plasma but not by the introduction of the lymphatic
drainage. We first evaluated the effects of changing the
clearance rate from our previous study [9] and adding lymphatic
transport for VEGF from the tissue to the vasculature in the absence
ofluminalreceptors.TheclearancerateforVEGFintheplasmawas
changed from 0.0206 min
21 (such that the VEGF half-life would be
around 34 min in plasma) to 0.0648 min
21 (corresponding to a
VEGF half-life of about 11 min). The flow rate of VEGF removal
through lymphatics wastaken to be2 cm
3/min. Figure 2A illustrates
the three scenarios we considered: scenario (a) corresponding to
our previous model [9] (clearance rate cV=0.0206min
21;n o
lymphatic drainage); scenario (b) is an intermediate step where
the clearance rate of VEGF has changed in the absence of lymphatic
drainage (clearance rate cV=0.0648min
21; no lymphatic drainage);
scenario (c) corresponds to our new baseline (clearance rate
cV=0.0648min
21; lymph flow rate kL=2cm
3/min).
The secretion rate of VEGF in the tissue was varied from 0.05
to 0.35 molecule/cell/s (Figure 2B). VEGF was expressed at a
ratio of 92%:8% for VEGF165:VEGF121 [13]. We considered
two vascular permeabilities for VEGF (4610
28 cm/s and
4610
27 cm/s). For clarity, we do not show curves that overlap.
The free VEGF concentration in the available interstitial fluid
(tissue compartment) was not significantly altered by the change of
clearance rate, the introduction of lymphatic drainage or the
change of permeability (blue curve corresponding to scenarios (a),
(b) and (c)). Increasing the clearance rate in the absence of
lymphatic drainage lowered the free VEGF level in the plasma
(purple and red curves comparing scenarios (a) and (b)). The
introduction of the lymphatic removal of VEGF did not change
the concentration of free VEGF significantly (red curve; scenarios
(b) and (c)). This result is in contrast to our previous study [7],
where we examined higher and a larger range of lymphatic
drainage rates for soluble proteins as a function of muscle activity
(lymphatic pump), which significantly affected free VEGF
concentration gradients between plasma and tissue interstitium.
As mentioned in our previous study [9], increasing the vascular
permeability to VEGF induced an increase of the plasma free
VEGF concentration (dotted vs. dashed curves) without signifi-
cantly altering the interstitial free VEGF level.
Increasing the vascular permeability to VEGF signifi-
cantly affected the free VEGF concentration in blood but
not in tissue. The different curves represented in Figure 2C
illustrate the VEGF concentration responses in available
interstitial fluid and plasma to vascular permeability for the
three scenarios illustrated in Figure 2A. Similar to that used in our
previous study [9], the baseline of each simulation was taken such
that, at a vascular permeability of 4610
28 cm/s, about 1 pM of
free VEGF was present in the plasma (black dot). This means that
the secretion rate had to be tuned for each simulation. The total
VEGF secretion rates were 0.1126 (dashed curve), 0.2634 (dashed-
dotted-dotted curve) and 0.2390 molecule/cell/s (solid curve) for
scenarios (a), (b) and (c) respectively. We then varied the vascular
permeability to VEGF from 4610
29 to 4610
26 cm/s. In all
scenarios, free VEGF concentration in the available interstitial
fluid was found to remain fairly constant over the range we
considered. Increasing the clearance rate required a higher free
VEGF concentration in the available interstitial fluid (blue dashed
vs. dashed-dotted-dotted curves, i.e., scenario (a) vs. (b)). This is
because a higher secretion was required to reach 1 pM of free
VEGF at steady state in plasma when the clearance rate was
increased. The introduction of the VEGF removal through the
lymphatics reduced the free VEGF level in the tissue (dashed-
dotted-dotted vs. solid curves, i.e., scenario (b) vs. (c)) since VEGF
was drained from the available interstitial fluid into the plasma
thus requiring a lower secretion rate to attain the 1 pM in the
plasma. A similar behavior was noted in the blood for a range of
vascular permeability higher than 4610
28 cm/s.
In our previous study [9], three regions were identified: for a
vascular permeability higher than 4610
26 cm/s, the free VEGF
concentration in the plasma converged to that in the available
interstitial fluid; for a vascular permeability lower than
4610
28 cm/s, free VEGF concentration in the plasma was fairly
constant and close to zero; and for a vascular permeability range
between 4610
28 to 10
26 cm/s, the free VEGF concentration was
approximately proportional to vascular permeability. These last
two regions could still be observed in Fig. 2C for scenarios (b) and
(c). However, it was clear that the new clearance rate and the
introduction of VEGF lymphatic drainage required a higher
vascular permeability for the free VEGF concentration in plasma
to equal that in the tissue (as compared to scenario (a)). This is due
to the fact that a higher net transport of VEGF from the tissue into
the blood compartment is required to compensate the loss of
VEGF with a higher clearance rate.
Table 4. Geometric parameters of the compartments [9].
Category Parameter Value Unit
Tissue compartment Total volume 61321 cm
3
Available fluid volume for VEGF 3825 cm
3
Blood compartment Total volume 5 L
Available fluid volume
for VEGF (plasma)
2.717 L
doi:10.1371/journal.pcbi.1000622.t004
Table 5. Kinetic parameters between the compartments and
in the blood.
Category Parameter Value Unit Reference
Inter-compartment Vascular permeability
to VEGF kp
4610
28 cm/s [9]
Lymph flow rate kL 120 mL/h [15]
2c m
3/min
Blood compartment Clearance rate
for VEGF cV
0.0648 min
21 [16]
doi:10.1371/journal.pcbi.1000622.t005
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vascular permeability as compared to the lymphatic
drainage. Figure 2D shows the variation of free VEGF
concentration in the tissue and plasma with the lymph flow rate.
The removal rate of VEGF through lymphatics was varied from 0
to 10 cm
3/min, i.e., 0 to 600 mL/h or 0 to 14.4 L/day. The
baseline was taken so that, at a vascular permeability of
4610
28 cm/s, a clearance rate of 0.0648 min
21 and a lymph
flow rate of 2 cm
3/min, about 1 pM of free VEGF was present in
the plasma (black dot on Figure 2D). Free VEGF level does not
change significantly in the tissue compartment. Within the tested
range, increasing the rate at which VEGF is removed through the
lymphatics increased the free VEGF concentration in the plasma.
However, this augmentation was less noticeable when the vascular
permeability was increased 10-fold (dotted vs. dashed curves): for a
vascular permeability of 4610
28 cm/s, the free VEGF
concentration in plasma varied from 0.89 to 1.44 pM (a 63%
increase), whereas at a vascular permeability of 4610
27 cm/s, it
varied from 5.01 to 5.31 pM (a 6% increase). This is due to
competition between the transendothelial exchange of free VEGF
(net permeability) and the lymphatic drainage of VEGF.
In the absence of clearance, the lymphatic drainage of
VEGF can invert the gradient of free VEGF concentration
across the endothelial barrier. We varied the clearance rate
for VEGF from 0 (which corresponds to an infinite half-life of
VEGF) to 0.09 min
21 (about 8-minute VEGF half-life). The
results are shown in Figure 2E. The free VEGF concentration in
the available interstitial fluid was fairly insensitive to the change of
clearance. However, the free VEGF level in plasma was
significantly affected by the variation of clearance. The
introduction of the lymphatics (red vs. light pink curves) did not
significantly change the free VEGF concentration for most of the
range of clearance rate studied. However, when the lymphatic
drainage was introduced and the clearance of VEGF was set to
zero (infinite half-life for VEGF in the plasma), the concentration
of free VEGF was higher in the plasma than in the available
interstitial fluid regardless of the vascular permeability to VEGF
for the range we checked. In such case, the gradient across the
endothelial cells (i.e., between the tissue and the blood
compartments) was inverted. In the absence of the lymphatics
and when the clearance was set to zero, the VEGF concentrations
were equal, as expected. This effect was not as drastic for a
Figure 2. Effects of VEGF secretion, vascular permeability, lymph flow rate and clearance. A. Three scenarios are studied: scenario (a) our
previous configuration from [9] (clearance rate cv=0.0206 min
21); scenario (b) new clearance cv=0.0648 min
21 in the absence of lymphatic drainage;
scenario (c) introduction of the lymphatic drainage of VEGF kL=2cm
3/min (120 mL/hour [15]) with the new clearance cv=0.0648 min
21. B. Effect of
VEGF secretion. Free VEGF concentration in the tissue is illustrated in blue. The purple curve corresponds to scenario (a) and the red curves to
scenarios (b) and (c) for the plasma VEGF concentration. We consider two permeability rates kp=4 610
28 cm/s (dotted curve) and 4610
27 cm/s
(dashed curve). C. Effect of vascular permeability to VEGF. Scenarios (a), (b) and (c) are represented as the dashed, dashed-dotted-dotted and solid
curves respectively. The blue curve corresponds to the tissue while the red curve corresponds to the blood. D. Effect of lymph flow rate. We only
consider scenarios (b) and (c) to look at the effect of adding the lymphatics to our model. We consider two permeability rates kp=4 610
28 cm/s
(dotted curve) and 4610
27 cm/s (dashed curve). The blue curve corresponds to the tissue while the red curve corresponds to the blood. E. Effect of
clearance rate. We consider two permeability rates kp=4 610
28 cm/s (dotted curve) and 4610
27 cm/s (dashed curve). The blue curve corresponds to
the tissue. The pink curve corresponds to scenarios (a) and (b) and the red curve corresponds to the scenario (c) of Figure 2A for the plasma VEGF
concentration.
doi:10.1371/journal.pcbi.1000622.g002
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27 cm/s due to increased
equilibration of the compartments by the intravasation/
extravasation of VEGF.
Effects of VEGF receptors on free VEGF concentrations in
available interstitial fluid and in plasma. We varied the
density of receptors on the luminal and abluminal surfaces on the
endothelial cells lining the capillaries and looked at the change of
free VEGF concentrations in the tissue and in the blood
compartments, as shown in Figure 3. The baseline was taken to
be 1 pM of free VEGF concentration in the plasma in the absence
of luminal receptors and in the presence of 10,000 VEGFR1,
10,000 VEGFR2 and 10,000 NRP1 on the abluminal side of the
endothelial cells [9]. Note that using a single-compartment model
of skeletal muscle we previously conducted a detailed sensitivity
analysis on the effect of receptor density on VEGF distribution
[18]. The vascular permeability was fixed at 4610
28 cm/s. The
clearance rate was 0.0648 min
21 and the lymph flow rate was set
at 2 cm
3/min. In this set of experiments, the secretion rate was not
changed across the simulations and the total VEGF secretion rate
was 0.2390 molecule/cell/s (with a VEGF expression rate
ratio VEGF121: VEGF165 of 92%:8%, i.e., VEGF165 secretion
rate=0.2199 molecule/cell/s and VEGF121 secretion rate=
0.0191 molecule/cell/s). Unless specified otherwise, the density
of receptors denotes the density of each species of receptors. For
example, ‘‘5,000 abluminal receptors per endothelial cell’’ means
‘‘5,000 of each species (VEGFR1, VEGFR2, and NRP-1) per
endothelial cell located on the abluminal surface.’’ The luminal
receptors were varied from 0 to 10,000 receptors per endothelial
cell. However, the fixed secretion rate was too high to reach a
steady state for an abluminal receptor density smaller than 2,500
receptors per endothelial cell. Increasing the density of luminal
receptors did not affect the free VEGF concentration in the
available interstitial fluid but drastically decreased that in the
plasma. Increasing the density of abluminal receptors decreased
the concentration of total free VEGF in both the tissue and the
blood compartments. This is due to receptor binding: the higher
the receptor density, the smaller the free VEGF concentration.
When the plasma concentration of free VEGF is fixed,
free VEGF concentration in the available interstitial
fluid is directly proportional to the density of luminal
receptors. The plasma free VEGF concentration was fixed at
1.00 pM at a vascular permeability of 4610
28 cm/s, a plasma
clearance rate of 0.0648 min
21 and a lymph flow rate of 2 cm
3/
min. Figure 4A summarizes the dependence of the flows of VEGF
(Figures 4Ai, iii, iv, v, vi, in pmoles/s) and the free VEGF
concentration in the available interstitial fluid (Figure 4Aii) on the
receptor densities on the luminal and abluminal surfaces of the
endothelial cells. Note that, for each simulation, we therefore
readjusted the VEGF secretion rate.
First, keeping the free VEGF concentration in plasma constant
fixes some of the outflows from the blood compartment since they
are directly proportional to the VEGF concentration. In other
words, the VEGF cleared from the blood was then constant
throughout the simulations (2.94610
23 pmoles/s) and so was the
rate of VEGF extravasation (2.65610
24 pmoles/s) as indicated on
the model diagram in Figure 4A. VEGF disappearing by
internalization of luminal ligated receptors (blood compartment)
was proportional to the density of receptors on the luminal surface
of the endothelial cells (Figure 4Aiv). This was explained by the
fact that the internalization terms of ligated receptors in the
equations were expressed as kint VR ½  . Since we assumed a fixed
total density of receptors at any time-step, i.e., R ½  z VR ½  ~ R ½  t~0,
VEGF disappearing by internalization of ligated receptors was
linearly dependent on the density of luminal receptors. VEGF flow
from the tissue to the blood compartment (intravasation and
lymphatic removal of VEGF) was also found to be directly
proportional to the density of luminal receptors (Figures 4Aiii and
4Av respectively). Although this may be surprising, it follows from
the balance of the inflows and outflows in the blood compartment.
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is also proportional to the density of
receptors on the luminal endothelial surface. Since these two
outflows differ only by a constant of proportionality, each term is
therefore linearly dependent on the density of luminal receptors.
These outflows are also directly proportional to the concentration
Figure 3. Free VEGF concentrations in tissue and blood as a
function of the receptor density. The secretion rate is fixed so that,
at a vascular permeability of 4610
28 cm/s, 1 pM of free VEGF is present
in the plasma (no luminal receptors; 10,000 abluminal receptors of each
species per endothelial cell). VEGF secretion rate is 0.2390 molecule/
cell/s. The density of abluminal and luminal receptors was varied from 0
to 10,000 receptors per endothelial cell surface. Note that no steady
state could be reached at such secretion rate in the absence of
abluminal receptors. The free VEGF concentration in the available
interstitial fluid was constant over the range of luminal receptor density
and decreased exponentially with the density of abluminal receptors.
The free VEGF concentration in the plasma was significantly changed
when the density of receptors was low.
doi:10.1371/journal.pcbi.1000622.g003
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PLoS Computational Biology | www.ploscompbiol.org 8 December 2009 | Volume 5 | Issue 12 | e1000622Figure 4. Flow diagrams for a fixed concentration of free VEGF in the plasma. A. The inflows and outflows are expressed in pmoles/s. The
density of luminal and abluminal receptors was varied from 0 to 10,000 per endothelial cell. Free VEGF concentration in the plasma was fixed at 1 pM
for a vascular permeability of 4610
28 cm/s. From top left, counter-clockwise: i. VEGF secreted per parenchymal cell; ii. free VEGF concentration in the
tissue (in pM); iii. VEGF intravasating; iv. VEGF disappearing through internalization of the luminal receptors to which it binds; v. VEGF drained
through the lymphatics; vi. VEGF disappearing through internalization of abluminal receptors to which it binds. VEGF extravasating and VEGF cleared
from the plasma are constant over the course of the simulations due to the fixed free VEGF concentration in the plasma and equal to 2.65610
24 and
2.94610
23 pmoles/s respectively. The yellow dot corresponds to the configuration of 10,000 abluminal receptors and no luminal receptors. The
purple dot identifies an equal density of receptors on luminal and abluminal surfaces of the endothelial cells (5,000 receptors on each side per
endothelial cell). The green dot corresponds to the case of 10,000 luminal receptors and no abluminal receptors. B. Flows normalized to VEGF
secretion for different luminal receptor densities: i. no abluminal receptors; ii. 500 abluminal receptors per EC; iii. 1,000 abluminal receptors per EC; iv.
10,000 abluminal receptors per EC. EC=endothelial cell.
doi:10.1371/journal.pcbi.1000622.g004
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dependence of free VEGF concentration in the tissue compart-
ment on the density of receptors on the luminal endothelial surface
(Figure 4Aii). Finally, VEGF secreted (Figure 4Ai) and VEGF
disappearing by internalization of its bound receptors on the
abluminal surface of the endothelial cells (Figure 4Avi) reach
saturation when the receptor density on the luminal endothelial
surface is high enough to push the free VEGF concentration
in the available interstitial fluid higher than Kd of VEGF and
its receptors (i.e., the saturation occurs when free VEGF in
the available interstitial fluid is several times higher than
Kd(VEGF,VEGFR)). Interestingly, VEGF secretion and internali-
zation through abluminal receptors were, however, linearly
dependent on the density of receptors on the abluminal endothelial
surface. This is mainly because the free plasma VEGF concentra-
tion was constant over the tested range of abluminal receptors.
Figure 4B shows the VEGF flows normalized to VEGF
secretion. The ratios are given in percentages. In the absence of
abluminal receptors (Figure 4Bi), most of the free VEGF
intravasates (.85%) regardless of the luminal receptor density
while, in the presence of abluminal receptors, most VEGF
disappears by internalization of abluminal ligated receptors
(Figures 4Bii–iv). When abluminal receptors are present, less than
25% of VEGF that has been secreted effectively enters the blood
compartment. Increasing the luminal receptor density yields more
VEGF entering the blood by intravasation. This is mainly due to
the fact that the model requires a higher secretion rate to balance
the increase in receptor density and internalization. Finally, unless
there are no luminal receptors (in which case free VEGF
disappears from the plasma by clearance), most free VEGF leaves
the blood by internalization of the luminal ligated receptors.
VEGF disappearing by internalization of abluminal
ligated receptors is proportional to VEGF secretion.
Noting similarity between Figures 4Ai and 4Avi, we mathe-
matically showed that VEGF secretion and VEGF disappearing by
internationalization of the abluminal receptors are proportional to
each other as illustrated in Figure 5A. The following mathematical
relationship was derived:
0~qN
V{kint ligated receptors ½  {
kLzkNB
pV SNB
UN
 !
V ½  N
KAV,N
zkBN
pV
SNB
UN
UB
Up
V ½  B
ð5Þ
This equation holds true not only for total VEGF but also for
each VEGF isoform individually and corresponds to the
conservation of VEGF molecules in the tissue compartment.
No linear relationship was found when looking at VEGF
disappearing by internalization of luminal ligated receptors (blood
compartment) in relation to the VEGF secreted as shown in
Figure 5B. However, the density of luminal receptors fixed the
internalization of ligated luminal receptors (dotted lines) but the
density of abluminal receptors dictated the form of the relationship
with secreted VEGF (solid lines).
When the receptors are evenly distributed on the
endothelial cell surface, the VEGF plasma clearance and
extravasation are minimized. We next examined how the
ratio of receptor densities on the luminal vs. abluminal endothelial
surface can impact transport. We fixed the density of total
receptors (luminal and abluminal) to 10,000 per endothelial cell.
Figure 6A illustrates three configurations. Scenario (a) represents
the case where all the receptors are located on the abluminal side
(tissue compartment), i.e., 10,000 receptors on the abluminal
endothelial surface and no luminal receptors in this representation.
This corresponds to the yellow dots on Figure 4A. Scenario (b)
represents the case where the receptors are evenly distributed
between the abluminal and luminal surfaces of the endothelial
cells, i.e., 5,000 receptors of each species are present in each
compartment. This corresponds to the purple dots on Figure 4A.
Finally, scenario (c) illustrates the case where all the receptors are
located on the luminal endothelial surface, i.e., 10,000 receptors
on the luminal surface of the endothelial cells and no abluminal
receptors. This corresponds to the green dots on Figure 4A. We
investigated how the inter- and intra-compartment flows of VEGF
vary between the configurations. We found that the transport of
VEGF by intravasation, lymphatic drainage, and internalization of
luminal ligated receptors increase when the receptors are
‘‘redistributed’’ from the abluminal to the luminal surface of the
endothelial cells. However, to maintain 1 pM of free VEGF in the
plasma, VEGF secretion varied significantly between the three
scenarios considered. For comparison purposes, we therefore
normalized the flows to VEGF secretion. These normalized
inflows and outflows are noted in terms of percentages of VEGF
secretion as indicated in parentheses in Figure 6A. Although the
clearance and the extravasation of VEGF were constant in terms
of absolute values (at 0.0029 and 0.0003 pmoles/s respectively, as
shown in Figures 4A and 6A), the corresponding normalized
values became minimal when the receptors were evenly distributed
between the luminal and the abluminal surfaces of the endothelial
cells (scenario (b) in Figure 6A).
Figure 6B generalizes these findings for more possible
configurations of a total of 10,000 receptors (of each species)
expressed per endothelial cell. The ratios of receptors on
abluminal:luminal endothelial surfaces are 10,000:0 (scenario (a)
in Figure 6A); 7,500:2,500; 5,000:5000 (scenario (b)); 2,500:7,500;
and 0:10,000 (scenario (c)). The net transendothelial VEGF flow is
the difference of VEGF intravasating and VEGF extravasating. As
long as abluminal receptors are present, most secreted VEGF
disappears by internalization upon binding to the abluminal
receptors. In the absence of abluminal receptors, intravasation is
the main route by which VEGF leaves the interstitial fluid. The
fraction of VEGF entering the plasma is, in all cases, mainly driven
by the permeability rather than by lymphatics.
VEGF is sequestered in the extracellular matrix when the
receptors are evenly distributed between the abluminal and
the luminal surfaces of the endothelial cells. Figure 7A
shows the distributions of VEGF when the total density of total
receptors (abluminal + luminal) was fixed at 10,000 receptors per
endothelial cell. The ratios of receptors on abluminal:luminal
endothelial surfaces are 10,000:0 (corresponding to scenario (a) in
Figure 6A); 7,500:2,500; 5,000:5000 (scenario (b)); 2,500:7,500;
and 0:10,000 (scenario (c)). In the absence of luminal receptors
(scenario (a) – bottom rows in Figures 7Ai and 7Aii), most VEGF is
in the form of the triplet VEGFR2-VEGF165-NRP1 (42%) while
about a quarter of VEGF is sequestered in the interstitium. In the
blood, free VEGF165 accounts for 92% of the total population of
VEGF. When there is an equal density of receptors on the
abluminal and luminal sides (‘‘even distribution’’ – scenario (b);
middle rows), about 75% of VEGF in the tissue is sequestered in
the interstitium. Interestingly, in the blood, most of the VEGF165 is
bound to VEGFR2 (or bridges VEGFR2-NRP1) while most of
VEGF121 is bound to VEGFR1 (or the VEGFR1-NRP1 complex).
These results were even more pronounced when all the receptors
were located on the luminal side (scenario (c) – top rows). One
striking result was that free VEGF121 represented between 0.07%
to 0.25% of the total VEGF distribution in the tissue (Figure 7Ai),
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the blood (Figure 7Aii) when the population of receptors ‘‘shifted’’
from the abluminal to the luminal surface of the endothelial cell.
Together with the results from Figure 6, this means that most of
the VEGF121 secreted in the tissue was cleared from the plasma or
disappeared by the internalization of the luminal receptors while
blood VEGF165 is in a form of the triplet VEGFR2-VEGF165-
NRP1. The increase of free VEGF121 in the tissue can also be
explained by the increasing sequestration of VEGF165 by the
ECM. Figure 7A demonstrates that the location of receptors on
the endothelial cells can drastically affect the VEGF distribution in
the plasma and in the tissue.
Figure 7B shows the receptor occupancies. In the absence of
receptors on one surface of the endothelial cells (scenario (a) or
(c) – top and bottom rows in Figures 7Bi and 7Bii), most of the
remaining receptors is in the form of the VEFGR1-NRP1 complex
while VEGFR2 is in its free state. This result does not change
significantly on the luminal endothelial surface when an equal
density is present on both luminal and abluminal surfaces of the
endothelial cells (scenario (b) – middle rows). However, in the
tissue, the occupancy of the receptors is ‘‘shifted’’ towards the
triplet VEGFR2-VEGF165-NRP1 which causes the population of
unbound VEGFR2 to be significantly reduced. In such case,
VEGFR1 is mainly bound by VEGF165 in the tissue.
In the tissue, more VEGF is bound to the ECM and less is
bound to the abluminal receptors as the density of
abluminal receptors decreases and the density of luminal
receptors increases. In the plasma, the amount of VEGF
bound to the luminal receptors is insensitive to the density of
abluminal receptors when VEGF plasma concentration is fixed.
Figure 8 illustrates the distribution of VEGF (free, bound to the
receptors, and sequestered in the matrix) when the receptor
density varies from 0 to 10,000 receptors per endothelial cell on
each surface of the endothelial cell. The three yellow (scenario (a)),
Figure 5. Flows of VEGF disappearing upon ligated receptor internalization as a function of the VEGF secreted. The setup is similar to
that in Figure 4. A. Linear relationship between the VEGF secreted and the VEGF disappearing via internalization of VEGF-bound abluminal receptors.
B. Non-linear relationship between the VEGF secreted and the VEGF disappearing via internalization of the luminal receptors it has bound to. Black
circles: no abluminal receptors; red circles: 2,500 abluminal receptors/endothelial cell; green triangles: 5,000 abluminal receptors/endothelial cell;
yellow triangles: 7,500 abluminal receptors/endothelial cell; blue squares: 10,000 abluminal receptors/endothelial cell.
doi:10.1371/journal.pcbi.1000622.g005
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receptors per endothelial cell is fixed at 10,000 (VEGFR1:VEGFR2:NRP1 expression is 1:1:1). Scenario (a): all the receptors are located on the endothelial
abluminal surface (yellow circle on Figure 4A); scenario (b): the receptors are evenly distributed between the luminal and abluminal endothelial
surface (purple circle on Figure 4A); scenario (c): all the receptors are located on the endothelial luminal surface. Numbers represent absolute values
of VEGF flows expressed in pmoles/s. Percentages of VEGF secretion in parentheses. B. Generalization of particular cases shown in A. The density of
receptors varies between 0 and 10,000 receptors per endothelial cell surface. The total receptor density is fixed at 10,000 receptors per endothelial
cell. Left: absolute values; Right: percentages of VEGF secretion.
doi:10.1371/journal.pcbi.1000622.g006
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cases studied in Figure 6A. We found that only a small fraction of
VEGF is free in the available interstitial fluid. Most VEGF is either
bound to the abluminal receptors or sequestered in the matrix.
VEGF is more and more bound to the receptors and less and less
sequestered in the matrix when the density of luminal receptors
decreases and the density of abluminal receptors increases. In the
blood, VEGF becomes more bound to the receptors with the
increasing density of luminal receptors but the general VEGF
distribution in this compartment does not significantly vary with
the abluminal receptor density across the interval tested.
Because the VEGF secretion occurs in the tissue, VEGF
binding to VEGFR1 and VEGFR2 takes place predominantly
on the abluminal surface of the endothelial cells, regardless
of the ratio of the receptors on each surface of endothelial
cell. We next looked at how much VEGF is bound to the
receptors on the abluminal surface of the endothelial cells as
compared to how much VEGF is bound to receptors on the luminal
surface of the endothelial cells. The ratio [VEGF bound to
abluminal VEGFR1]/[VEGF bound to luminal VEGFR1] is
shown in Figure 9A and the ratio [VEGF bound to abluminal
VEGFR2]/[VEGF bound to luminal VEGFR2] is illustrated in
Figure 9B. For most cases, these two ratios were higher than 1,
meaning that the amount of VEGF bound to VEGFR1 or
VEGFR2 was higher on the abluminal than on the luminal
surface of the endothelial cells. This is explained by the fact that the
VEGF secretion occurs in the tissue, leading to a VEGF gradient
from the tissue to the blood compartment. However, a small region
revealed more binding on the luminal side (ratio ,1) for VEGFR2
(Figure 9B). This small region corresponds to low abluminal and
high luminal receptordensities.Thisregionrevealsreceptorbinding
for VEGFR1 higher on the abluminal endothelial surface
(Figure 9A). Therefore, at low abluminal and high luminal
receptor densities, there is more binding to VEGFR1 on the
abluminal surface and more binding to VEGFR2 on the luminal
surface. This particular region calls for experimental exploration.
Figure 7. VEGF distribution and VEGFR occupancy for a total receptor density of 10,000 per endothelial cells. The scenarios
correspond to those in Figure 6B. A. VEGF distribution. i. tissue; ii. blood. Columns from left to right: total VEGF distribution, VEGF165 distribution,
VEGF121 distribution. In the absence of luminal receptors (bottom rows in i. and ii.), most VEGF bridges VEGFR2-NRP1 in the tissue and
VEGF165:VEGF121 in the plasma is 92%:8% similar to that of the isoforms expressions in the tissue. When abluminal receptor density decreases, VEGF is
increasingly sequestered in the extracellular matrix (ECM, PBM, EBM) in the tissue compartment and VEGF165 bridges VEGFR2-NRP1 in the plasma. B.
VEGFR occupancy. i. tissue; ii. blood. Columns from left to right: total VEGFR occupancy, VEGFR1 occupancy, VEGFR2 occupancy, NRP1 occupancy.
When the receptors are distributed on one side of the endothelial cells (either luminal or abluminal), most of the VEGF receptors are in the form of
VEGFR1-NRP1 complex while most of VEGFR2 is in its free state (bottom row in i. and top row in ii.). When the receptors are distributed evenly
between the endothelial cells luminal and abluminal surfaces, the luminal receptor occupancy remains unchanged (top and middle rows in ii.) but
the VEGF receptor occupancy in the tissue shifts towards VEGF165 bridging VEGFR2-NRP1 (bottom and middle rows in i.).
doi:10.1371/journal.pcbi.1000622.g007
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bound to VEGFR1 as compared to bound to VEGFR2. VEGFR2
is pro-angiogenic, whereas VEGFR1 is anti-angiogenic or
modulatory [19], thus the ratio might represent pro- vs. anti-
angiogenic signaling. Figure 9C illustrates the ratio [VEGF bound
to VEGFR2]/[VEGF bound to VEGFR1] in each compartment
(i.e., the abluminal and luminal surfaces of the endothelial cells). If
this ratio is higher than 1, then VEGF is predominantly bound to
VEGFR2. Conversely, if the ratio is lower than 1, then VEGF is
predominantly bound to VEGFR1. Figure 9C shows that the two
ratios are always higher than 1 in both the tissue and the blood
compartments for our region of interest, meaning that the VEGF
binds more to VEGFR2 than to VEGFR1, even though the total
VEGFR1 and VEGFR2 densities are assumed equal (as
mentioned previously, VEGFR1:VEGFR2:NRP1 are expressed
on each endothelial cell surface in 1:1:1 ratio). Since the Kd for
VEGF-VEGFR2 is three times higher than the Kd for VEGF-
VEGFR1 binding, this means that this cannot be the consequence
of a higher binding affinity for VEGFR2 but rather of the
neuropilin-1 presence. We also note that the higher the receptor
density on the abluminal endothelial surface, the more binding to
VEGFR2 (as compared to VEGFR1) on this same surface.
However, the magnitude of the ratio is much higher on the
luminal endothelial surface (blood compartment) than on the
abluminal endothelial surface (tissue compartment). This is most
likely because only a small fraction of free VEGF intravasates
(Figure 8).
Discussion
This extension of our previous model [9] is useful for exploring
the effects of luminal vs. abluminal distribution of VEGF receptors
ontheendothelialsurfaces.Wehave shown thatsuchconfigurations
candrastically affecttheVEGF profileinthetissue andinthe blood.
First, we have shown that the removal of clearance in the
presence of lymphatics could reverse the free VEGF gradient
between the tissue and the blood compartments. Such a situation
might correspond to certain pathological conditions, but the
simulation is also instructive as a characterization of the VEGF
transport system. However, it is important to note that our current
model does not explicitly include the convective component of
transvascular permeability and such addition could attenuate the
predicted gradient reversal. Secondly, at a fixed VEGF secretion
rate, the free VEGF in the available interstitial fluid is much higher
than that in the plasma. When the free VEGF concentration in the
plasma is constant (,1 pM), VEGF extravasation and plasma
VEGF clearance over time are constant over the range of
receptors we studied. We have found that the amount of VEGF
disappearing by internalization of luminal receptors to which it
binds, the amount of VEGF extravasating and the amount of
VEGF removal from lymphatic drainage are all proportional to
the luminal receptor density but insensitive to the abluminal
receptor density. We have established a mathematical relationship
between the amount of VEGF secreted and VEGF disappearing
by internalization of abluminal receptors. Thirdly, we can
Figure 8. VEGF distributions in the tissue and in the blood. The setup is similar to that in Figure 4. Top row: VEGF distribution in the tissue;
bottom row: VEGF distribution in the blood. The first column corresponds to the percentage of free VEGF; the second column the percentage of VEGF
bound to the receptors; the third column the percentage of VEGF bound to the extracellular matrix and basement membranes.
doi:10.1371/journal.pcbi.1000622.g008
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as shown in Figure 10. VEGF is secreted in the tissue. Depending
on the receptor density on the abluminal and luminal endothelial
surfaces, VEGF is mainly either sequestered by the matrix or binds
to abluminal receptors. Upon binding, VEGF disappears by
internalization of the abluminal receptors it has bound to. Only a
small fraction (free ligands) enters the blood compartment (mainly
by intravasation rather than lymphatic drainage). VEGF then
disappears either by internalization of receptors located on the
luminal endothelial surface to which they bind or, when the
receptor densities are very low, by plasma clearance. This overall
transport explains why, regardless of where the receptors are
expressed on the endothelial cells (abluminal vs. luminal surfaces),
the binding to the receptors occurs more in the tissue than in the
plasma (since a higher concentration of free ligands is available in
this compartment – due to secretion – as compared to the free
VEGF in the blood). However, our simulations have revealed that
for high abluminal and low luminal receptor densities, VEGF can
bind ‘‘preferentially’’ to VEGFR1 on the abluminal surface and to
VEGFR2 on the luminal surface of the endothelial cells. This
result requires experimental exploration. In particular, this result
shows that quantification of luminal vs. abluminal receptors can be
crucial in understanding VEGF signaling in both physiological and
pathological conditions. Finally, our simulations reveal that VEGF
binds ‘‘preferentially’’ to VEGFR2 compared to VEGFR1. If
VEGFR2 is shown to be pro-angiogenic and VEGFR1 is shown to
be anti-angiogenic, then we can conclude that, overall, the
signaling is mainly pro-angiogenic regardless of the receptor
distribution on the endothelial cells.
Since VEGF receptor distribution between the abluminal and
luminal endothelial surfaces plays such an important role, it would
be interesting to investigate if some pathologies could be explained
by decreased receptor expression or internalization. For example,
in our previous model, we had shown that an increase in VEGF
vascular permeability or secretion could not solely explain the
increase of free VEGF concentration in plasma seen in cancer
patients [9]. It could be interesting to see if deregulated receptor
expression could explain the plasma VEGF increase in cancer (as
Figure 9. VEGF signaling. A. Ratio [VEGF bound to abluminal VEGFR1]/[VEGF bound to luminal VEGFR1]. B. Ratio [VEGF bound to abluminal
VEGFR2]/[VEGF bound to luminal VEGFR2]. C. Ratio [VEGF bound to VEGFR2]/[VEGF bound to VEGFR1]. Top row: tissue; bottom row: blood.
doi:10.1371/journal.pcbi.1000622.g009
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example, that VEGF could intravasate in high proportion if the
amount of VEGF disappearing by internalization of bound
receptors decreases, i.e., if the internalization rate of the receptors
or if the receptors expression decreases.
The present model also suggests that, since most of VEGF
disappears via internalization of bound receptors (whether on the
luminal or abluminal endothelial surface), the increase of
internalization of receptors could potentially decrease VEGF
signal transduction. This could be done either by increasing the
internalization rate of the already-existing receptors or by
bioengineering cells expressing VEGF receptors which would
have the property of having a high binding affinity for VEGF as
well as a higher internalization rates than endothelial cells.
Decreasing the VEGF signal transduction of endothelial cells
could have potential therapeutic applications.
For a complex system such as the VEGF receptor-ligand
interactions and transport considered, it is necessary to add
elements and further increase the degree of complexity step by
step in order to understand the effect of each factor. We can
outline further steps in refining the model. First, the model has
looked at the effect of the receptors in the proportion 1:1:1 for
VEGFR1:VEGFR2:NRP1. It would also be of interest to see how
unequal ratios of receptors can influence the distribution and
concentration of VEGF, especially when experimental data on
receptor distribution in vivo become available. Secondly, at the
moment, the model considers two isoforms of VEGF: VEGF121
and VEGF165. Other isoforms could be added to the computa-
tional model when new quantitative information becomes
available. The model could also include neuropilin-2 which could
compete for VEGF. Thirdly, the introduction of soluble VEGFR1
(sFlt-1) would also be of interest, especially since recent results have
shown that sFlt-1 can serve as an additional means for VEGF to be
transported from the plasma into the tissue [7]. In that study, we
hypothesized that the anti-angiogenic potential of sVEGFR1 may
stem from its dominant-negative heterodimerization with cell
surface VEGFRs and predicted that the circulating (plasma) level
of sVEGFR1 is significantly higher than its interstitial concentra-
tions, which could imply that sVEGFR1 may have a greater
modulatory influence on luminal VEGFRs than abluminal
VEGFRs [7,11].
Platelets have been shown to be significant reservoirs of VEGF in
the blood circulation. It would be interesting to include suchelements
into the model. Again, quantification of luminal receptors would
be crucial, especially since platelets have been shown to sequester
large amounts of VEGF and release VEGF from a-granules [20,21].
Similarly, the body tissue compartment was considered to have
the properties of skeletal muscle. It could be important to
distinguish between highly vascularized and relatively avascular
organs, as well as elements with varying rates of lymphatic
drainage. This would require experimental data on VEGF
secretion and other tissue characteristics that at present are poorly
known. Furthermore, luminal and abluminal receptors may not be
equally accessible by VEGF possibly because of endothelial cell
polarity: basement membrane on the abluminal side and
glycocalyx on the luminal side.
A current assumption was the conservation of total (free and
bound) density of receptors at each time step. In other words, we
assumed that the internalization of receptors was equal to the
receptor insertion per abluminal or luminal endothelial surface for
each time point. Relaxing such assumptions and replacing them by
the experimentally-based receptor dynamics would make the
model more accurate.
In our model, we assumed that the vascular permeability was
fixed. In reality, VEGF, also known as VPF (vascular permeability
factor), plays an important role in regulating permeability [22]. An
addition to the model would be to determine a quantitative
relationship between the vascular permeability and the concen-
tration of VEGF and include that relationship in the model.
Our study has shown that quantification of luminal vs.
abluminal receptors could be very useful to better understand
VEGF signaling and the mechanisms underlying VEGF-depen-
dent diseases as well as angiogenesis and will motivate experi-
mental exploration.
Acknowledgments
The authors thank Elena Rosca, Amina Qutub, Emmanouil
Karagiannis, Princess Imoukhuede, Jacob Koskimaki and Prakash
Vempati for useful discussions.
Supporting Information
Text S1 Glossary and system of equations in the absence of
luminal receptors and lymphatic drainage
Found at: doi:10.1371/journal.pcbi.1000622.s001 (0.05 MB PDF)
Author Contributions
Conceived and designed the experiments: MOS FTHW FMG ASP.
Performed the experiments: MOS. Analyzed the data: MOS FTHW FMG
ASP. Wrote the paper: MOS FTHW FMG ASP.
References
1. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth
factor. Endocr Rev 18: 4–25.
2. Mac Gabhann F, Popel AS (2008) Systems biology of vascular endothelial
growth factors. Microcirculation 15: 715–738.
Figure 10. Summary of VEGF transport in the body. VEGF is
secreted by parenchymal cells in the tissue. Most of VEGF is sequestered
in the extracellular matrix or binds to the abluminal receptors and
disappears by VEGF-bound receptor internalization. A small fraction
(free VEGF) is transported from the available interstitial fluid to the
plasma (mostly through the permeability route rather than by the
lymphatics). Upon entering the blood, free VEGF either binds to luminal
receptors and disappears by VEGF-bound receptor internalization or is
cleared from the plasma.
doi:10.1371/journal.pcbi.1000622.g010
Effects of VEGF Receptors
PLoS Computational Biology | www.ploscompbiol.org 16 December 2009 | Volume 5 | Issue 12 | e10006223. Roskoski R, Jr. (2007) Vascular endothelial growth factor (VEGF) signaling in
tumor progression. Crit Rev Oncol Hematol 62: 179–213.
4. Harper SJ, Bates DO (2008) VEGF-A splicing: the key to anti-angiogenic
therapeutics? Nat Rev Cancer 8: 880–887.
5. Shinkaruk S, Bayle M, Lain G, Deleris G (2003) Vascular endothelial cell growth
factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem
Anticancer Agents 3: 95–117.
6. Pan Q, Chathery Y, Wu Y, Rathore N, Tong RK, et al. (2007) Neuropilin-1
binds to VEGF121 and regulates endothelial cell migration and sprouting. J Biol
Chem 282: 24049–24056.
7. Wu FT, Stefanini MO, Mac Gabhann F, Popel AS (2009) A compartment
model of VEGF distribution in humans in the presence of soluble VEGF
receptor-1 acting as a ligand trap. PLoS One 4: e5108.
8. Ferrara N, Henzel WJ (1989) Pituitary follicular cells secrete a novel heparin-
binding growth factor specific for vascular endothelial cells. Biochem Biophys
Res Commun 161: 851–858.
9. Stefanini MO, Wu FT, Mac Gabhann F, Popel AS (2008) A compartment
model of VEGF distribution in blood, healthy and diseased tissues. BMC Syst
Biol 2: 77.
10. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH (2003) Platelets
and granulocytes, in particular the neutrophils, form important compartments
for circulating vascular endothelial growth factor. Angiogenesis 6: 283–287.
11. Wu FT, Stefanini MO, Gabhann FM, Kontos CD, Annex BH, et al. (2009)
Computational kinetic model of VEGF trapping by soluble VEGF receptor-1:
effects of transendothelial and lymphatic macromolecular transport. Physiol
Genomics 38: 29–41.
12. Feng D, Nagy JA, Brekken RA, Pettersson A, Manseau EJ, et al. (2000)
Ultrastructural localization of the vascular permeability factor/vascular
endothelial growth factor (VPF/VEGF) receptor-2 (FLK-1, KDR) in normal
mouse kidney and in the hyperpermeable vessels induced by VPF/VEGF-
expressing tumors and adenoviral vectors. J Histochem Cytochem 48: 545–556.
13. Ng YS, Rohan R, Sunday ME, Demello DE, D’Amore PA (2001) Differential
expression of VEGF isoforms in mouse during development and in the adult.
Dev Dyn 220: 112–121.
14. Aukland K, Nicolaysen G (1981) Interstitial fluid volume: local regulatory
mechanisms. Physiol Rev 61: 556–643.
15. Guyton AC (1981) The lymphatic system, interstitial fluid dynamics, edema, and
pulmonary fluid. Textbook of Medical Physiology. 6th ed: W.B. Saunders
Company.
16. Eppler SM, Combs DL, Henry TD, Lopez JJ, Ellis SG, et al. (2002) A target-
mediated model to describe the pharmacokinetics and hemodynamic effects of
recombinant human vascular endothelial growth factor in humans. Clin
Pharmacol Ther 72: 20–32.
17. Kut C, Mac Gabhann F, Popel AS (2007) Where is VEGF in the body? A meta-
analysis of VEGF distribution in cancer. Br J Cancer 97: 978–985.
18. Mac Gabhann F, Popel AS (2007) Interactions of VEGF isoforms with VEGFR-
1, VEGFR-2, and neuropilin in vivo: a computational model of human skeletal
muscle. Am J Physiol Heart Circ Physiol 292: H459–474.
19. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, et al. (2003) Role
of PlGF in the intra- and intermolecular cross talk between the VEGF receptors
Flt1 and Flk1. Nat Med 9: 936–943.
20. Italiano JE, Jr., Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, et al.
(2008) Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic
proteins are organized into separate platelet alpha granules and differentially
released. Blood 111: 1227–1233.
21. Wartiovaara U, Salven P, Mikkola H, Lassila R, Kaukonen J, et al. (1998)
Peripheral blood platelets express VEGF-C and VEGF which are released
during platelet activation. Thromb Haemost 80: 171–175.
22. Roberts WG, Palade GE (1995) Increased microvascular permeability and
endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci
108(Pt 6): 2369–2379.
23. Gavin TP, Robinson CB, Yeager RC, England JA, Nifong LW, et al. (2004)
Angiogenic growth factor response to acute systemic exercise in human skeletal
muscle. J Appl Physiol 96: 19–24.
24. Kiens B, Roemen TH, van der Vusse GJ (1999) Muscular long-chain fatty acid
content during graded exercise in humans. Am J Physiol 276: E352–357.
25. Sjogaard G, Saltin B (1982) Extra- and intracellular water spaces in muscles of
man at rest and with dynamic exercise. Am J Physiol 243: R271–280.
26. Saltin B (1985) Malleability of the system in overcoming limitations: functional
elements. J Exp Biol 115: 345–354.
27. Hernandez N, Torres SH, Finol HJ, Vera O (1999) Capillary changes in skeletal
muscle of patients with essential hypertension. Anat Rec 256: 425–432.
28. Magalha ˜es J, Ascensa ˜o A, Marques, Soares J, Neuparth M, et al. (2005) Skeletal
muscle ultrastructural and plasma biochemical signs of endothelium dysfunction
induced by a high-altitude expedition (Pumori, 7161 m). Basic Appl Myol 15:
29–35.
Effects of VEGF Receptors
PLoS Computational Biology | www.ploscompbiol.org 17 December 2009 | Volume 5 | Issue 12 | e1000622